RRC ID 58779
著者 Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H.
タイトル Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.
ジャーナル Cancer Immunol Immunother
Abstract Colorectal cancer (CRC) patients with metastatic lesions have low 5-year survival rates. During metastasis, cancer cells often obtain unique characteristics such as epithelial-mesenchymal transition (EMT). Vimentin a biomarker contributes to EMT by changing cell shape and motility. Since abnormal phosphorylation is a hallmark of malignancy, targeting phosphorylated vimentin is a feasible approach for the treatment of metastatic tumors while sparing non-tumor cells. Recent evidence has revealed that both CD8 cytotoxic T lymphocytes (CTLs) and also CD4 helper T lymphocytes (HTLs) can distinguish post-translationally modified antigens from normal antigens. Here, we showed that the expression of phosphorylated vimentin was upregulated in metastatic sites of CRC. We also showed that a chemotherapeutic reagent augmented the expression of phosphorylated vimentin. The novel phosphorylated helper peptide epitopes from vimentin could elicit a sufficient T cell response. Notably, precursor lymphocytes that specifically reacted to these phosphorylated vimentin-derived peptides were detected in CRC patients. These results suggest that immunotherapy targeting phosphorylated vimentin could be promising for metastatic CRC patients.
巻・号 69(6)
ページ 989-999
公開日 2020-6-1
DOI 10.1007/s00262-020-02524-9
PII 10.1007/s00262-020-02524-9
PMID 32086539
MeSH Adult Aged Cell Line Cell Line, Tumor Colorectal Neoplasms / drug therapy* Colorectal Neoplasms / pathology Female Humans Immunotherapy / methods* Male Middle Aged Neoplasm Metastasis Vimentin / pharmacology Vimentin / therapeutic use*
IF 5.442
引用数 0
リソース情報
ヒト・動物細胞 Sa3(RCB0980) LU65(RCB1967)